September 22, 2020
Article
Bruton tyrosine kinase (BTK) inhibitors play an important role in the therapeutic spectrum of B-cell lymphomas.
September 14, 2020
Video
Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.
September 11, 2020
Article
Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.
September 11, 2020
Article
Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.
September 10, 2020
Article
Kami J. Maddocks, MD, discusses the utility of BTK inhibitors in B-cell malignancies, challenges that are still faced in the space, and areas primed for additional development.
September 09, 2020
Video
Shuo Ma, MD, PhD, highlights ongoing research with BTK inhibitors in B-cell malignancies.
September 09, 2020
Video
Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.
August 19, 2020
Article
Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.
July 20, 2020
Video
John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.
July 14, 2020
Video
Steven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.
July 14, 2020
Video
Kami J. Maddocks, MD, discusses the role of zanubrutinib in B-cell malignancies.
March 23, 2020
Article
Constantine S. Tam, MD, MBBS, highlights the impact of BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia.
March 20, 2020
Article
Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.
March 20, 2020
Article
During an OncLive® Scientific Interchange, community and academic oncologists review the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-cell lymphomas.
February 12, 2020
Video
Constantine S. Tam, MD, MBBS, discusses the 3 FDA approved BTK inhibitors in hematologic malignancies: ibrutinib, acalabrutinib, and zanubrutinib.
February 12, 2020
Video
Constantine S. Tam, MD, MBBS, discusses the FDA approval of zanubrutinib in mantle cell lymphoma.
February 12, 2020
Video
Brad Kahl, MD, discusses trials looking at time-definite therapy looking at BTK inhibitor combinations in chronic lymphocytic leukemia.
January 08, 2020
Video
Constantine S. Tam, MD, MBBS, discusses a comparison of BTK inhibitors in mantle cell lymphoma.
January 02, 2020
Video
Brad Kahl, MD, discusses choosing between BTK inhibitors ibrutinib and acalabrutinib for frontline treatment of chronic lymphocytic leukemia.